MedPath

ALLERGAN AUSTRALIA PTY LIMITED

šŸ‡¦šŸ‡ŗAustralia
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Phase 1
Completed
Conditions
Ocular Hypertension
Glaucoma
Interventions
Drug: AGN-210669 ophthalmic solution, 0.025%
Drug: AGN-210669 ophthalmic solution, 0.05%
Drug: bimatoprost ophthalmic solution 0.03%
Drug: AGN-210669 ophthalmic solution, 0.075%
Drug: AGN-210669 vehicle ophthalmic solution
First Posted Date
2008-12-17
Last Posted Date
2013-10-18
Lead Sponsor
Allergan
Target Recruit Count
172
Registration Number
NCT00809848

Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema

Phase 2
Completed
Conditions
Vitrectomy
Diabetic Macular Edema
Interventions
Drug: Dexamethasone
First Posted Date
2008-11-27
Last Posted Date
2019-04-23
Lead Sponsor
Allergan
Target Recruit Count
56
Registration Number
NCT00799227

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

Phase 4
Completed
Conditions
Inflammation
Interventions
Drug: Ketorolac 0.4%
Drug: Lubricating Eye Drop
First Posted Date
2008-11-14
Last Posted Date
2011-09-23
Lead Sponsor
Allergan
Target Recruit Count
9
Registration Number
NCT00791323

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

Phase 2
Completed
Conditions
Choroidal Neovascularization
Age-Related Maculopathy
Interventions
Drug: dexamethasone
Biological: ranibizumab
First Posted Date
2008-10-20
Last Posted Date
2012-09-03
Lead Sponsor
Allergan
Target Recruit Count
44
Registration Number
NCT00775411

Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm

Phase 4
Completed
Conditions
Blepharospasm
Interventions
Biological: Botulinum Toxin Type A 900kDa
Biological: Botulinum Toxin Type A 150kDa
First Posted Date
2008-09-29
Last Posted Date
2013-11-19
Lead Sponsor
Allergan
Target Recruit Count
65
Registration Number
NCT00761592

Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms

First Posted Date
2008-09-29
Last Posted Date
2013-11-19
Lead Sponsor
Allergan
Target Recruit Count
50
Registration Number
NCT00761202

Efficacy and Acceptability of Two Lubricant Eye Drops

Phase 4
Completed
Conditions
Dry Eye Syndromes
Interventions
Drug: Lubricant Eye Drops (Optiveā„¢)
Drug: Lubricating Eye Drops (blinkĀ® Tears)
First Posted Date
2008-09-22
Last Posted Date
2011-10-31
Lead Sponsor
Allergan
Target Recruit Count
51
Registration Number
NCT00756678

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects

Phase 4
Completed
Conditions
Glaucoma
Ocular Hypertension
Interventions
Drug: Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%
Drug: timolol maleate 0.5%
Drug: latanoprost 0.005%
First Posted Date
2008-08-15
Last Posted Date
2019-04-23
Lead Sponsor
Allergan
Target Recruit Count
204
Registration Number
NCT00735449

Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease

Completed
Conditions
Keratoconjunctivitis Sicca
Interventions
Drug: cyclosporine ophthalmic emulsion 0.05%, artificial tears
First Posted Date
2008-07-17
Last Posted Date
2012-01-12
Lead Sponsor
Allergan
Target Recruit Count
781
Registration Number
NCT00717418

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Completed
Conditions
Open-Angle Glaucoma
Ocular Hypertension
Interventions
Drug: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
First Posted Date
2008-07-16
Last Posted Date
2012-01-06
Lead Sponsor
Allergan
Target Recruit Count
1099
Registration Number
NCT00716742
Ā© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy